161 related articles for article (PubMed ID: 28471656)
1. 4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Gallus J; Wiese M
J Med Chem; 2017 May; 60(10):4474-4495. PubMed ID: 28471656
[TBL] [Abstract][Full Text] [Related]
2. 2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
Krapf MK; Gallus J; Namasivayam V; Wiese M
J Med Chem; 2018 Sep; 61(17):7952-7976. PubMed ID: 30075623
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
Krapf MK; Gallus J; Spindler A; Wiese M
Eur J Med Chem; 2019 Jan; 161():506-525. PubMed ID: 30390439
[TBL] [Abstract][Full Text] [Related]
4. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
Silbermann K; Li J; Namasivayam V; Baltes F; Bendas G; Stefan SM; Wiese M
J Med Chem; 2020 Sep; 63(18):10412-10432. PubMed ID: 32787102
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
6. New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
Krapf MK; Gallus J; Vahdati S; Wiese M
J Med Chem; 2018 Apr; 61(8):3389-3408. PubMed ID: 29547272
[TBL] [Abstract][Full Text] [Related]
7. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
[TBL] [Abstract][Full Text] [Related]
8. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
Krapf MK; Wiese M
J Med Chem; 2016 Jun; 59(11):5449-61. PubMed ID: 27148793
[TBL] [Abstract][Full Text] [Related]
10. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
[TBL] [Abstract][Full Text] [Related]
11. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
12. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Hofman J; Sorf A; Vagiannis D; Sucha S; Kammerer S; Küpper JH; Chen S; Guo L; Ceckova M; Staud F
Mol Pharm; 2019 Nov; 16(11):4436-4450. PubMed ID: 31633365
[TBL] [Abstract][Full Text] [Related]
13. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
15. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
17. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
18. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
[TBL] [Abstract][Full Text] [Related]
19. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive Evaluation of Multidrug Resistance via Imaging of ABCG2/BCRP Multidrug Transporter in Lung Cancer Xenograft Models.
Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
